1 |
Kim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y. N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., Ko, T., Han, J., Kim, H. L., Kim, J., Back, S. H., Komatsu, M., Chen, H., Chan, D. C., Konishi, M., Itoh, N., Choi, C. S. and Lee, M. S. 2013. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 19, 83-92.
DOI
|
2 |
Kim, S. H., Kim, K. H., Kim, H. K., Kim, M. J., Back, S. H., Konishi, M., Itoh, N. and Lee, M. S. 2015. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia 58, 809-818.
DOI
|
3 |
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A. and Kuro-o, M. 2007. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687-26695.
DOI
|
4 |
Lewis, J. E., Ebling, F. J. P., Samms, R. J. and Tsintzas, K. 2019. Going back to the biology of FGF21: New insights. Trends Endocrinol. Metab. 30, 491-504.
DOI
|
5 |
Liang, Q., Zhong, L., Zhang, J., Wang, Y., Bornstein, S. R., Triggle, C. R., Ding, H., Lam, K. S. and Xu, A. 2014. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63, 4064-4075.
DOI
|
6 |
Lin, Z., Tian, H., Lam, K. S., Lin, S., Hoo, R. C., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A. and Li, X. 2013. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 779-789.
DOI
|
7 |
Oishi, K., Konishi, M., Murata, Y. and Itoh, N. 2011. Timeimposed daily restricted feeding induces rhythmic expression of Fgf21 in white adipose tissue of mice. Biochem. Biophys. Res. Commun. 412, 396-400.
DOI
|
8 |
Owen, B. M., Ding, X., Morgan, D. A., Coate, K. C., Bookout, A. L., Rahmouni, K., Kliewer, S. A. and Mangelsdorf, D. J. 2014. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 20, 670-677.
DOI
|
9 |
Owen, B. M., Mangelsdorf, D. J. and Kliewer, S. A. 2015. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 26, 22-29.
DOI
|
10 |
Samms, R. J., Cheng, C. C., Kharitonenkov, A., Gimeno, R. E. and Adams, A. C. 2016. Overexpression of beta-Klotho in adipose tissue sensitizes male mice to endogenous FGF21 and provides protection from diet-induced obesity. Endocrinology 157, 1467-1480.
DOI
|
11 |
Song, P., Zechner, C., Hernandez, G., Canovas, J., Xie, Y., Sondhi, V., Wagner, M., Stadlbauer, V., Horvath, A., Leber, B., Hu, M. C., Moe, O. W., Mangelsdorf, D. J. and Kliewer, S. A. 2018. The hormone FGF21 stimulates water drinking in response to ketogenic diet and alcohol. Cell Metab. 27, 1338-1347. e1334.
DOI
|
12 |
Stemmer, K., Zani, F., Habegger, K. M., Neff, C., Kotzbeck, P., Bauer, M., Yalamanchilli, S., Azad, A., Lehti, M., Martins, P. J., Muller, T. D., Pfluger, P. T. and Seeley, R. J. 2015. FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice. Diabetologia 58, 2414-2423.
DOI
|
13 |
Weng, Y., Ishino, T., Sievers, A., Talukdar, S., Chabot, J. R., Tam, A., Duan, W., Kerns, K., Sousa, E., He, T., Logan, A., Lee, D., Li, D., Zhou, Y., Bernardo, B., Joyce, A., Kavosi, M., O'Hara, D. M., Clark, T., Guo, J., Giragossian, C., Stahl, M., Calle, R. A., Kriz, R., Somers, W. and Lin, L. 2018. Glyco-engineered long acting FGF21 variant with optimal pharmaceutical and pharmacokinetic properties to enable weekly to twice monthly subcutaneous dosing. Sci. Rep. 8, 4241.
DOI
|
14 |
Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B. M., Brenner, M. B., Trimmer, J. K., Gropp, K. E., Chabot, J. R., Erion, D. M., Rolph, T. P., Goodwin, B. and Calle, R. A. 2016. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23, 427-440.
DOI
|
15 |
Tan, B. K., Hallschmid, M., Adya, R., Kern, W., Lehnert, H. and Randeva, H. S. 2011. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 60, 2758-2762.
DOI
|
16 |
Tyynismaa, H., Carroll, C. J., Raimundo, N., Ahola-Erkkila, S., Wenz, T., Ruhanen, H., Guse, K., Hemminki, A., Peltola-Mjosund, K. E., Tulkki, V., Oresic, M., Moraes, C. T., Pietilainen, K., Hovatta, I. and Suomalainen, A. 2010. Mitochondrial myopathy induces a starvation-like response. Hum. Mol. Genet. 19, 3948-3958.
DOI
|
17 |
Kwon, M. M., O'Dwyer, S. M., Baker, R. K., Covey, S. D. and Kieffer, T. J. 2015. FGF21-mediated improvements in glucose clearance require uncoupling protein 1. Cell Rep. 13, 1521-1527.
DOI
|
18 |
Goetz, R., Ohnishi, M., Kir, S., Kurosu, H., Wang, L., Pastor, J., Ma, J., Gai, W., Kuro-o, M., Razzaque, M. S. and Mohammadi, M. 2012. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J. Biol. Chem. 287, 29134-29146.
DOI
|
19 |
Kharitonenkov, A. and Shanafelt, A. B. 2009. FGF21: a novel prospect for the treatment of metabolic diseases. Curr. Opin. Investig. Drugs 10, 359-364.
|
20 |
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D. S., Mehrbod, F., Jaskunas, S. R. and Shanafelt, A. B. 2005. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635.
DOI
|
21 |
Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A. and Burgess, S. C. 2009. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. USA. 106, 10853-10858.
DOI
|
22 |
Laeger, T., Albarado, D. C., Burke, S. J., Trosclair, L., Hedgepeth, J. W., Berthoud, H. R., Gettys, T. W., Collier, J. J., Munzberg, H. and Morrison, C. D. 2016. Metabolic responses to dietary protein restriction require an increase in FGF21 that is delayed by the absence of GCN2. Cell Rep. 16, 707-716.
DOI
|
23 |
Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M. and Potthoff, M. J. 2014. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63, 4057-4063.
DOI
|
24 |
Mu, J., Pinkstaff, J., Li, Z., Skidmore, L., Li, N., Myler, H., Dallas-Yang, Q., Putnam, A. M., Yao, J., Bussell, S., Wu, M., Norman, T. C., Rodriguez, C. G., Kimmel, B., Metzger, J. M., Manibusan, A., Lee, D., Zaller, D. M., Zhang, B. B., DiMarchi, R. D., Berger, J. P. and Axelrod, D. W. 2012. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61, 505-512.
DOI
|
25 |
Veniant, M. M., Sivits, G., Helmering, J., Komorowski, R., Lee, J., Fan, W., Moyer, C. and Lloyd, D. J. 2015. Pharmacologic effects of FGF21 are independent of the "Browning" of white adipose tissue. Cell Metab. 21, 731-738.
DOI
|
26 |
Wu, A. L., Kolumam, G., Stawicki, S., Chen, Y., Li, J., Zavala-Solorio, J., Phamluong, K., Feng, B., Li, L., Marsters, S., Kates, L., van Bruggen, N., Leabman, M., Wong, A., West, D., Stern, H., Luis, E., Kim, H. S., Yansura, D., Peterson, A. S., Filvaroff, E., Wu, Y. and Sonoda, J. 2011. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 3, 113ra126.
DOI
|
27 |
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y. S., Lindberg, R. A., Chen, J. L., Jung, D. Y., Zhang, Z., Ko, H. J., Kim, J. K. and Veniant, M. M. 2009. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259.
DOI
|
28 |
Adams, A. C., Cheng, C. C., Coskun, T. and Kharitonenkov, A. 2012. FGF21 requires betaklotho to act in vivo. PLoS One 7, e49977.
DOI
|
29 |
Ameka, M., Markan, K. R., Morgan, D. A., BonDurant, L. D., Idiga, S. O., Naber, M. C., Zhu, Z., Zingman, L. V., Grobe, J. L., Rahmouni, K. and Potthoff, M. J. 2019. Liver derived FGF21 maintains core body temperature during acute cold exposure. Sci. Rep. 9, 630.
DOI
|
30 |
Bookout, A. L., de Groot, M. H., Owen, B. M., Lee, S., Gautron, L., Lawrence, H. L., Ding, X., Elmquist, J. K., Takahashi, J. S., Mangelsdorf, D. J. and Kliewer, S. A. 2013. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 19, 1147-1152.
DOI
|
31 |
Chartoumpekis, D. V., Habeos, I. G., Ziros, P. G., Psyrogiannis, A. I., Kyriazopoulou, V. E. and Papavassiliou, A. G. 2011. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol. Med. 17, 736-740.
DOI
|
32 |
Coate, K. C., Hernandez, G., Thorne, C. A., Sun, S., Le, T. D. V., Vale, K., Kliewer, S. A. and Mangelsdorf, D. J. 2017. FGF21 is an exocrine pancreas secretagogue. Cell Metab. 25, 472-480.
DOI
|
33 |
De Sousa-Coelho, A. L., Relat, J., Hondares, E., Perez-Marti, A., Ribas, F., Villarroya, F., Marrero, P. F. and Haro, D. 2013. FGF21 mediates the lipid metabolism response to amino acid starvation. J. Lipid Res. 54, 1786-1797.
DOI
|
34 |
Desai, B. N., Singhal, G., Watanabe, M., Stevanovic, D., Lundasen, T., Fisher, F. M., Mather, M. L., Vardeh, H. G., Douris, N., Adams, A. C., Nasser, I. A., FitzGerald, G. A., Flier, J. S., Skarke, C. and Maratos-Flier, E. 2017. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol. Metab. 6, 1395-1406.
DOI
|
35 |
Diaz-Delfin, J., Hondares, E., Iglesias, R., Giralt, M., Caelles, C. and Villarroya, F. 2012. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153, 4238-4245.
DOI
|
36 |
Ding, X., Boney-Montoya, J., Owen, B. M., Bookout, A. L., Coate, K. C., Mangelsdorf, D. J. and Kliewer, S. A. 2012. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16, 387-393.
DOI
|
37 |
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S. and Maratos-Flier, E. 2010. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781-2789.
DOI
|
38 |
Fisher, F. M., Kim, M., Doridot, L., Cunniff, J. C., Parker, T. S., Levine, D. M., Hellerstein, M. K., Hudgins, L. C., Maratos-Flier, E. and Herman, M. A. 2017. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol. Metab. 6, 14-21.
DOI
|
39 |
Samms, R. J., Smith, D. P., Cheng, C. C., Antonellis, P. P., Perfield, J. W., 2nd, Kharitonenkov, A., Gimeno, R. E. and Adams, A. C. 2015. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep. 11, 991-999.
DOI
|
40 |
Shenoy, V. K., Beaver, K. M., Fisher, F. M., Singhal, G., Dushay, J. R., Maratos-Flier, E. and Flier, S. N. 2016. Elevated serum fibroblast growth factor 21 in humans with acute pancreatitis. PLoS One 11, e0164351.
DOI
|
41 |
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K. and Moller, D. E. 2013. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333-340.
DOI
|
42 |
Ge, X., Chen, C., Hui, X., Wang, Y., Lam, K. S. and Xu, A. 2011. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J. Biol. Chem. 286, 34533-34541.
DOI
|
43 |
Giralt, M., Gavalda-Navarro, A. and Villarroya, F. 2015. Fibroblast growth factor-21, energy balance and obesity. Mol. Cell. Endocrinol. 418 Pt 1, 66-73.
DOI
|
44 |
Hill, C. M., Laeger, T., Dehner, M., Albarado, D. C., Clarke, B., Wanders, D., Burke, S. J., Collier, J. J., Qualls-Creekmore, E., Solon-Biet, S. M., Simpson, S. J., Berthoud, H. R., Munzberg, H. and Morrison, C. D. 2019. FGF21 signals protein status to the brain and adaptively regulates food choice and metabolism. Cell Rep. 27, 2934-2947. e2933.
DOI
|
45 |
BonDurant, L. D., Ameka, M., Naber, M. C., Markan, K. R., Idiga, S. O., Acevedo, M. R., Walsh, S. A., Ornitz, D. M. and Potthoff, M. J. 2017. FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. Cell Metab. 25, 935-944. e934.
DOI
|
46 |
Adams, A. C., Yang, C., Coskun, T., Cheng, C. C., Gimeno, R. E., Luo, Y. and Kharitonenkov, A. 2012. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2, 31-37.
DOI
|
47 |
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M. and Evans, R. M. 2013. PPARgamma signaling and metabolism: the good, the bad and the future. Nat. Med. 19, 557-566.
DOI
|
48 |
Badman, M. K., Koester, A., Flier, J. S., Kharitonenkov, A. and Maratos-Flier, E. 2009. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150, 4931-4940.
DOI
|
49 |
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S. and Maratos-Flier, E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426-437.
DOI
|
50 |
Berglund, E. D., Li, C. Y., Bina, H. A., Lynes, S. E., Michael, M. D., Shanafelt, A. B., Kharitonenkov, A. and Wasserman, D. H. 2009. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150, 4084-4093.
DOI
|
51 |
Chau, M. D., Gao, J., Yang, Q., Wu, Z., and Gromada, J. 2010. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc. Natl. Acad. Sci. USA. 107, 12553-12558.
DOI
|
52 |
Collaborators, G. B. D. O., Afshin, A., Forouzanfar, M. H., Reitsma, M. B., Sur, P., Estep, K., Lee, A., Marczak, L., Mokdad, A. H., Moradi-Lakeh, M., Naghavi, M., Salama, J. S., Vos, T., Abate, K. H., Abbafati, C., Ahmed, M. B., Al-Aly, Z., Alkerwi, A., Al-Raddadi, R., Amare, A. T., Amberbir, A., Amegah, A. K., Amini, E., Amrock, S. M., Anjana, R. M., Arnlov, J., Asayesh, H., Banerjee, A., Barac, A., Baye, E., Bennett, D. A., Beyene, A. S., Biadgilign, S., Biryukov, S., Bjertness, E., Boneya, D. J., Campos-Nonato, I., Carrero, J. J., Cecilio, P., Cercy, K., Ciobanu, L. G., Cornaby, L., Damtew, S. A., Dandona, L., Dandona, R., Dharmaratne, S. D., Duncan, B. B., Eshrati, B., Esteghamati, A., Feigin, V. L., Fernandes, J. C., Furst, T., Gebrehiwot, T. T., Gold, A., Gona, P. N., Goto, A., Habtewold, T. D., Hadush, K. T., Hafezi-Nejad, N., Hay, S. I., Horino, M., Islami, F., Kamal, R., Kasaeian, A., Katikireddi, S. V., Kengne, A. P., Kesavachandran, C. N., Khader, Y. S., Khang, Y. H., Khubchandani, J., Kim, D., Kim, Y. J., Kinfu, Y., Kosen, S., Ku, T., Defo, B. K., Kumar, G. A., Larson, H. J., Leinsalu, M., Liang, X., Lim, S. S., Liu, P., Lopez, A. D., Lozano, R., Majeed, A., Malekzadeh, R., Malta, D. C., Mazidi, M., McAlinden, C., McGarvey, S. T., Mengistu, D. T., Mensah, G. A., Mensink, G. B. M., Mezgebe, H. B., Mirrakhimov, E. M., Mueller, U. O., Noubiap, J. J., Obermeyer, C. M., Ogbo, F. A., Owolabi, M. O., Patton, G. C., Pourmalek, F., Qorbani, M., Rafay, A., Rai, R. K., Ranabhat, C. L., Reinig, N., Safiri, S., Salomon, J. A., Sanabria, J. R., Santos, I. S., Sartorius, B., Sawhney, M., Schmidhuber, J., Schutte, A. E., Schmidt, M. I., Sepanlou, S. G., Shamsizadeh, M., Sheikhbahaei, S., Shin, M. J., Shiri, R., Shiue, I., Roba, H. S., Silva, D. A. S., Silverberg, J. I., Singh, J. A., Stranges, S., Swaminathan, S., Tabares-Seisdedos, R., Tadese, F., Tedla, B. A., Tegegne, B. S., Terkawi, A. S., Thakur, J. S., Tonelli, M., Topor-Madry, R., Tyrovolas, S., Ukwaja, K. N., Uthman, O. A., Vaezghasemi, M., Vasankari, T., Vlassov, V. V., Vollset, S. E., Weiderpass, E., Werdecker, A., Wesana, J., Westerman, R., Yano, Y., Yonemoto, N., Yonga, G., Zaidi, Z., Zenebe, Z. M., Zipkin, B. and Murray, C. J. L. 2017. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377, 13-27.
DOI
|
53 |
Douris, N., Stevanovic, D. M., Fisher, F. M., Cisu, T. I., Chee, M. J., Nguyen, N. L., Zarebidaki, E., Adams, A. C., Kharitonenkov, A., Flier, J. S., Bartness, T. J. and Maratos-Flier, E. 2015. Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 156, 2470-2481.
DOI
|
54 |
Dutchak, P. A., Katafuchi, T., Bookout, A. L., Choi, J. H., Yu, R. T., Mangelsdorf, D. J. and Kliewer, S. A. 2012. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556-567.
DOI
|
55 |
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., Elmquist, J. K., Gerard, R. D., Burgess, S. C., Hammer, R. E., Mangelsdorf, D. J. and Kliewer, S. A. 2007. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415-425.
DOI
|
56 |
Holland, W. L., Adams, A. C., Brozinick, J. T., Bui, H. H., Miyauchi, Y., Kusminski, C. M., Bauer, S. M., Wade, M., Singhal, E., Cheng, C. C., Volk, K., Kuo, M. S., Gordillo, R., Kharitonenkov, A. and Scherer, P. E. 2013. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790-797.
DOI
|
57 |
Hondares, E., Rosell, M., Gonzalez, F. J., Giralt, M., Iglesias, R. and Villarroya, F. 2010. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 11, 206-212.
DOI
|
58 |
Huang, Z., Zhong, L., Lee, J. T. H., Zhang, J., Wu, D., Geng, L., Wang, Y., Wong, C. M. and Xu, A. 2017. The FGF21-CCL11 axis mediates beiging of white adipose tissues by coupling sympathetic nervous system to Type 2 immunity. Cell Metab. 26, 493-508. e494.
DOI
|
59 |
Fisher, F. M. and Maratos-Flier, E. 2016. Understanding the Physiology of FGF21. Annu. Rev. Physiol. 78, 223-241.
DOI
|
60 |
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E. and Spiegelman, B. M. 2012. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26, 271-281.
DOI
|
61 |
Foltz, I. N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., Weiszmann, J., Stevens, J., Chen, J. S., Nuanmanee, N., Gupte, J., Komorowski, R., Sekirov, L., Hager, T., Arora, T., Ge, H., Baribault, H., Wang, F., Sheng, J., Karow, M., Wang, M., Luo, Y., McKeehan, W., Wang, Z., Veniant, M. M. and Li, Y. 2012. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci. Transl. Med. 4, 162ra153.
DOI
|
62 |
Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J. and Kliewer, S. A. 2010. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050-2064.
DOI
|
63 |
Kharitonenkov, A., Dunbar, J. D., Bina, H. A., Bright, S., Moyers, J. S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S. F., Knierman, M. D., Hale, J. E., Coskun, T. and Shanafelt, A. B. 2008. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215, 1-7.
DOI
|
64 |
Jiang, S., Yan, C., Fang, Q. C., Shao, M. L., Zhang, Y. L., Liu, Y., Deng, Y. P., Shan, B., Liu, J. Q., Li, H. T., Yang, L., Zhou, J., Dai, Z., Liu, Y. and Jia, W. P. 2014. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J. Biol. Chem. 289, 29751-29765.
DOI
|
65 |
Johnson, C. L., Mehmood, R., Laing, S. W., Stepniak, C. V., Kharitonenkov, A. and Pin, C. L. 2014. Silencing of the Fibroblast growth factor 21 gene is an underlying cause of acinar cell injury in mice lacking MIST1. Am. J. Physiol. Endocrinol. Metab. 306, E916-928.
DOI
|
66 |
Katafuchi, T., Holland, W. L., Kollipara, R. K., Kittler, R., Mangelsdorf, D. J. and Kliewer, S. A. 2018. PPARgamma-K107 SUMOylation regulates insulin sensitivity but not adiposity in mice. Proc. Natl. Acad. Sci. USA. 115, 12102-12111.
DOI
|